GlassScriptPhysician profile
Heidi Mattison
NPI 1043667520
$1,623.12
in general payments reported to CMS, 2019-2025
24 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $364 · 2023: $65.89 · 2024: $185 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $253.32 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $251.51 | 2021-2023 | Xtampza |
| Janssen Pharmaceuticals, INC | $167.76 | 2024-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $96.47 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $94.76 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Medtronic, INC. | $84.56 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $77.34 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $59.03 | 2025 | Cobenfy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.80 | 2021-2023 | Relistor |
| Boston Scientific Corporation | $49.46 | 2025 | Wavewriter Alpha Prime 16 |
| Arbor Pharmaceuticals, INC. | $48.29 | 2021-2022 | |
| Pfizer INC. | $47.68 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $43.58 | 2021-2022 | |
| Amgen INC. | $40.71 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $40.53 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.26 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $31.83 | 2022-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $28.87 | 2021 | |
| Lundbeck LLC | $24.08 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $20.88 | 2025 | Auvelity |
| Allergan, INC. | $20.36 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.21 | 2022 | |
| Abbott Laboratories | $16.61 | 2022 | |
| Corium, LLC | $15.22 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Mattison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.